Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box
Autor: | Rahul D. Tendulkar, James R. Broughman, C.W. Fleming |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty medicine.medical_treatment Clinical Decision-Making Disease Multimodal Imaging Systemic therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Recurrence Prostate Internal medicine Biomarkers Tumor medicine Humans Pharmacology (medical) Neoplasm Metastasis Oligometastatic disease Neoplasm Staging business.industry Disease Management Prostatic Neoplasms Treatment options Pet imaging Prognosis medicine.disease Combined Modality Therapy Treatment Outcome 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Lymphadenectomy business |
Zdroj: | Current Treatment Options in Oncology. 22 |
ISSN: | 1534-6277 1527-2729 |
Popis: | Due to its relatively indolent disease course, the sensitivity of PSA testing, and the emergence of novel PET imaging, metastatic prostate cancer is particularly likely to present with a limited volume of disease. Patients with up to five metastatic lesions should be considered for an oligometastatic treatment approach. Systemic therapy remains the cornerstone of treatment for these patients. The optimal type and duration are unknown; however, the addition of a second agent to ADT appears to be beneficial. Multiple recent studies have found significant benefits to the integration of systemic therapy and local metastasis-directed therapies (MDT), including radiation and surgery, to the prostate and metastatic sites. MDT may also be used in select patients wishing to delay the initiation of systemic therapy. For patients with isolated regional nodal recurrences, whole pelvic radiotherapy or extensive lymphadenectomy is preferred, in combination with ADT. |
Databáze: | OpenAIRE |
Externí odkaz: |